JP2017532302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532302A5 JP2017532302A5 JP2017512684A JP2017512684A JP2017532302A5 JP 2017532302 A5 JP2017532302 A5 JP 2017532302A5 JP 2017512684 A JP2017512684 A JP 2017512684A JP 2017512684 A JP2017512684 A JP 2017512684A JP 2017532302 A5 JP2017532302 A5 JP 2017532302A5
- Authority
- JP
- Japan
- Prior art keywords
- tev
- utr
- sequence
- human
- gaopt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108020004705 Codon Proteins 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000049953 human LEP Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046487P | 2014-09-05 | 2014-09-05 | |
| US62/046,487 | 2014-09-05 | ||
| PCT/US2015/048535 WO2016037053A1 (en) | 2014-09-05 | 2015-09-04 | Lipids and lipid compositions for the delivery of active agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532302A JP2017532302A (ja) | 2017-11-02 |
| JP2017532302A5 true JP2017532302A5 (OSRAM) | 2018-10-18 |
| JP6731912B2 JP6731912B2 (ja) | 2020-07-29 |
Family
ID=54256820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512684A Active JP6731912B2 (ja) | 2014-09-05 | 2015-09-04 | 活性物質の送達用の脂質および脂質組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10125092B2 (OSRAM) |
| EP (1) | EP3188760B1 (OSRAM) |
| JP (1) | JP6731912B2 (OSRAM) |
| CN (1) | CN107072946B (OSRAM) |
| ES (1) | ES2969956T3 (OSRAM) |
| WO (1) | WO2016037053A1 (OSRAM) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052107B1 (en) | 2013-10-04 | 2018-05-02 | Novartis AG | Organic compounds to treat hepatitis b virus |
| CN105683163B (zh) | 2013-10-04 | 2018-11-09 | 诺华股份有限公司 | RNA干扰中使用的RNAi剂的3’端帽 |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| JP6731912B2 (ja) * | 2014-09-05 | 2020-07-29 | ノバルティス アーゲー | 活性物質の送達用の脂質および脂質組成物 |
| WO2017038650A1 (ja) * | 2015-08-28 | 2017-03-09 | 積水メディカル株式会社 | ベンジル化合物 |
| MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
| LT3436077T (lt) * | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2017208191A1 (en) | 2016-06-02 | 2017-12-07 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| JP2019528312A (ja) * | 2016-08-07 | 2019-10-10 | ノバルティス アーゲー | ｍＲＮＡ媒介性の免疫化方法 |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US11780885B2 (en) | 2016-11-17 | 2023-10-10 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| CN110891553A (zh) | 2017-05-30 | 2020-03-17 | 葛兰素史密丝克莱恩生物有限公司 | 制造包封rna的脂质体的方法 |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| CN111108203A (zh) * | 2017-07-17 | 2020-05-05 | 葛兰素史密丝克莱恩生物有限公司 | 狂犬病病毒抗原构建体 |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| WO2020035609A2 (en) | 2018-08-17 | 2020-02-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| CN109260174B (zh) * | 2018-09-04 | 2021-10-15 | 中山大学 | 一种治疗性蛋白纳米颗粒的高通量制备方法 |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| DK3646854T3 (da) * | 2018-10-30 | 2022-09-26 | Polyplus Transfection | Sammensætninger til transfektion af mRNA i en celle og anvendelser deraf |
| KR20210108969A (ko) | 2018-12-05 | 2021-09-03 | 인텔리아 테라퓨틱스, 인크. | 변형된 아민 지질 |
| WO2020121273A1 (en) | 2018-12-14 | 2020-06-18 | Glaxosmithkline Biologicals Sa | Heterologous prime boost vaccine compositions and methods |
| MX2021010808A (es) * | 2019-03-08 | 2021-12-15 | Massachusetts Inst Technology | Ácido ribonucleico replicón-nanopartículas sinteticas oncolítico y sintético y usos para inmunoterapia de cáncer. |
| US20220273789A1 (en) | 2019-07-21 | 2022-09-01 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
| WO2021038508A1 (en) | 2019-08-30 | 2021-03-04 | Glaxosmithkline Biologicals Sa | Jet mixing lipid nanoparticle manufacturing process |
| AU2020382378A1 (en) * | 2019-11-15 | 2022-06-30 | Daiichi Sankyo Company, Limited | Nucleic acid lipid particle vaccine encapsulating HPV mRNA |
| IL294318A (en) | 2020-01-09 | 2022-08-01 | Guide Therapeutics Llc | Nanomaterials |
| US20240269266A1 (en) * | 2020-04-14 | 2024-08-15 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| EP4135761A1 (en) | 2020-04-16 | 2023-02-22 | GlaxoSmithKline Biologicals S.A. | Sars cov-2 spike protein construct |
| US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| US20230256090A1 (en) | 2020-06-29 | 2023-08-17 | Glaxosmithkline Biologicals Sa | Adjuvants |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022137128A2 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
| US12059477B2 (en) | 2021-01-20 | 2024-08-13 | Beam Therapeutics Inc. | Nanomaterials |
| CA3203628A1 (en) | 2021-01-20 | 2022-07-28 | Beam Therapeutics Inc. | Nanomaterials comprising a biodegradable feature |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| CN113993839B (zh) * | 2021-02-05 | 2024-02-09 | 嘉晨西海(杭州)生物技术有限公司 | 一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用 |
| CN112961065B (zh) * | 2021-02-05 | 2023-03-14 | 嘉晨西海(杭州)生物技术有限公司 | 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| CA3212653A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| EP4342993A4 (en) * | 2021-05-19 | 2025-05-28 | Daiichi Sankyo Company, Limited | Hpv infectious disease vaccine |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| US20240272143A1 (en) | 2021-06-09 | 2024-08-15 | Glaxosmithkline Biologicals Sa | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| US20250134824A1 (en) | 2021-08-16 | 2025-05-01 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
| CA3240127A1 (en) * | 2021-12-07 | 2023-06-15 | Zihao Wang | Rna formulations and lipids |
| CN118401547A (zh) * | 2021-12-17 | 2024-07-26 | 嘉晨西海(杭州)生物技术有限公司 | 白细胞介素-12自我复制rna和方法 |
| JP2023130120A (ja) * | 2022-03-07 | 2023-09-20 | スペラファーマ株式会社 | ペプチド合成方法 |
| CN119072464A (zh) * | 2022-03-25 | 2024-12-03 | 赛欧生物医药股份有限公司 | 新型可电离脂质和脂质纳米颗粒以及其使用方法 |
| JP2023181989A (ja) * | 2022-06-13 | 2023-12-25 | 上海臻上医薬科技有限公司 | マイクロニードル注射製剤およびその使用 |
| CN119604304A (zh) | 2022-06-18 | 2025-03-11 | 葛兰素史克生物有限公司 | 包含非翻译区或编码来自严重急性呼吸道冠状病毒2奥密克戎毒株刺突蛋白的区段的重组rna分子 |
| WO2024019936A1 (en) | 2022-07-20 | 2024-01-25 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4608812A1 (en) * | 2022-10-28 | 2025-09-03 | Advanced RNA Vaccine (ARV) Technologies, Inc. | Vitamin-based lipids and lipid nanoparticles comprising the same |
| CN120265278A (zh) * | 2022-12-07 | 2025-07-04 | 嘉晨西海(杭州)生物技术有限公司 | 自我复制rna疫苗和使用方法 |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
| EP4658239A1 (en) | 2023-02-03 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024187158A1 (en) * | 2023-03-08 | 2024-09-12 | The Regents Of The University Of California | Benzaldehyde acetal acid-degradable amphiphilic lipid and self-assembling peptides |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025011529A2 (en) | 2023-07-07 | 2025-01-16 | Shanghai Circode Biomed Co., Ltd. | Circular rna vaccines for seasonal flu and methods of uses |
| WO2025045142A1 (en) | 2023-08-29 | 2025-03-06 | Shanghai Circode Biomed Co., Ltd. | Circular rna encoding vegf polypeptides, formulations, and methods of uses |
| WO2025067389A1 (en) * | 2023-09-28 | 2025-04-03 | Immorna (hangzhou) Biotechnology Co., Ltd. | Lipid complex nanoparticle for lung-targeted delivery of nucleic acid therapeutic agent |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025140618A1 (zh) * | 2023-12-29 | 2025-07-03 | 康希诺(上海)生物研发有限公司 | 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途 |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025229572A1 (en) | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU675482B2 (en) | 1992-12-04 | 1997-02-06 | Innovir Laboratories, Inc. | Ribozyme amplified diagnostics |
| JPH08507203A (ja) | 1992-12-04 | 1996-08-06 | イノーバー ラボラトリーズ，インコーポレイテッド | 調節可能な核酸治療およびそれらの使用方法 |
| US5871914A (en) | 1993-06-03 | 1999-02-16 | Intelligene Ltd. | Method for detecting a nucleic acid involving the production of a triggering RNA and transcription amplification |
| WO1995008986A1 (en) | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
| US6958239B2 (en) | 1996-11-21 | 2005-10-25 | Oligos Etc Inc. | Three component chimeric antisense oligonucleotides |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| EP0958303A4 (en) | 1996-12-19 | 2004-03-31 | Univ Yale | BIOREACTIVE ALLOSTERIC POLYNUCLEOTIDES |
| US20030036517A1 (en) | 1997-12-05 | 2003-02-20 | Bruce A. Sullenger | Nucleic acid mediated rna tagging and rna revision |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| IL126731A0 (en) | 1998-10-23 | 1999-08-17 | Intelligene Ltd | A method of detection |
| EP1133513A4 (en) | 1998-11-03 | 2002-07-03 | Univ Yale | MULTI-DOMAIN POLYNUCLEOTIDE MOLECULAR DETECTORS |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7112337B2 (en) * | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| EP1423142A1 (en) | 2001-08-31 | 2004-06-02 | Chiron SRL. | Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins |
| JP4896715B2 (ja) | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物 |
| EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| CA2566559C (en) | 2004-05-17 | 2014-05-06 | Inex Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| ES2595363T3 (es) | 2005-02-18 | 2016-12-29 | J. Craig Venter Institute, Inc. | Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| BRPI0609460A2 (pt) | 2005-03-30 | 2010-04-13 | Novartis Vaccines & Diagnostics Inc | haemophilus influenzae tipo b |
| EP1891096A2 (en) | 2005-05-12 | 2008-02-27 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
| DK1927584T3 (en) * | 2005-09-20 | 2017-02-20 | Jitsubo Co Ltd | CARRIER FOR SEPARATION, PROCEDURE FOR SEPARATION OF CONNECTION AND PROCEDURE FOR SYNTHESIS OF PEPTIDE USING THE CARRIER |
| EP1954306A2 (en) | 2005-10-25 | 2008-08-13 | Novartis Vaccines and Diagnostics S.r.l. | Compositions comprising yersinia pestis antigens |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
| CN101903018B (zh) * | 2007-10-17 | 2012-09-05 | 韩国科学技术院 | 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法 |
| ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
| WO2009109860A2 (en) | 2008-03-06 | 2009-09-11 | Novartis Ag | Mutant forms of chlamydia htra |
| CA2758490C (en) | 2009-04-14 | 2023-05-02 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| US20110300205A1 (en) | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
| EP3721943A1 (en) | 2009-12-23 | 2020-10-14 | Novartis AG | Lipids, lipid compositions and methods of using them |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| JP2014101274A (ja) * | 2011-03-09 | 2014-06-05 | Jitsubo Co Ltd | 新規な架橋構造を含むｔｎｆレセプターループペプチドの模倣ペプチドを用いた医薬組成物 |
| ES2742299T3 (es) * | 2011-03-09 | 2020-02-13 | Jitsubo Co Ltd | Nuevos péptidos entrecruzados que contienen una estructura entrecruzada no peptídica, método para sintetizar péptidos entrecruzados y nuevo compuesto orgánico utilizado en el método |
| CA2856742A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| JP6136934B2 (ja) | 2011-12-15 | 2017-05-31 | 味の素株式会社 | Ｆｍｏｃ基の除去方法 |
| US9504747B2 (en) * | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| JP6731912B2 (ja) * | 2014-09-05 | 2020-07-29 | ノバルティス アーゲー | 活性物質の送達用の脂質および脂質組成物 |
| CN110891553A (zh) * | 2017-05-30 | 2020-03-17 | 葛兰素史密丝克莱恩生物有限公司 | 制造包封rna的脂质体的方法 |
| WO2020121273A1 (en) * | 2018-12-14 | 2020-06-18 | Glaxosmithkline Biologicals Sa | Heterologous prime boost vaccine compositions and methods |
-
2015
- 2015-09-04 JP JP2017512684A patent/JP6731912B2/ja active Active
- 2015-09-04 US US15/505,282 patent/US10125092B2/en active Active
- 2015-09-04 ES ES15775528T patent/ES2969956T3/es active Active
- 2015-09-04 EP EP15775528.1A patent/EP3188760B1/en active Active
- 2015-09-04 CN CN201580060043.1A patent/CN107072946B/zh active Active
- 2015-09-04 WO PCT/US2015/048535 patent/WO2016037053A1/en not_active Ceased
-
2018
- 2018-09-19 US US16/135,116 patent/US10844002B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532302A5 (OSRAM) | ||
| JP2017048194A5 (OSRAM) | ||
| JP2019194236A5 (OSRAM) | ||
| JP2016104790A5 (OSRAM) | ||
| JP2013539454A5 (OSRAM) | ||
| JP2018520997A5 (OSRAM) | ||
| JP2010227108A5 (OSRAM) | ||
| JP2017186358A5 (OSRAM) | ||
| EA202191418A1 (ru) | Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения | |
| JP2020022459A5 (OSRAM) | ||
| EA201892250A1 (ru) | Вакцина против rsv | |
| JP2011155981A5 (OSRAM) | ||
| JP2018504907A5 (OSRAM) | ||
| JP2017153484A5 (OSRAM) | ||
| JP2010065037A5 (OSRAM) | ||
| JP2015096070A5 (OSRAM) | ||
| JP2016518328A5 (OSRAM) | ||
| JP2017534262A5 (OSRAM) | ||
| JP2018033454A5 (OSRAM) | ||
| EA201692361A1 (ru) | Лентивирусные векторы | |
| JP2016539629A5 (OSRAM) | ||
| EA201990628A1 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| JP2021502388A5 (OSRAM) | ||
| JP2010088434A5 (OSRAM) | ||
| JP2012505657A5 (OSRAM) |